CARGO Therapeutics, Inc.
CRGX
$4.12
$0.071.73%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 110.21% | 178.52% | 268.77% | 304.15% | 287.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 93.74% | 136.66% | 184.29% | 183.30% | 178.13% |
| Operating Income | -93.74% | -136.66% | -184.29% | -183.30% | -178.13% |
| Income Before Tax | -70.66% | -93.12% | -160.81% | -162.14% | -139.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.66% | -93.12% | -160.81% | -162.14% | -139.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.66% | -93.12% | -160.81% | -162.14% | -139.67% |
| EBIT | -93.74% | -136.66% | -184.29% | -183.30% | -178.13% |
| EBITDA | -93.99% | -137.03% | -184.39% | -182.69% | -177.07% |
| EPS Basic | 96.15% | 96.47% | 50.17% | 23.94% | 6.89% |
| Normalized Basic EPS | 95.99% | 96.35% | 48.20% | 20.88% | 10.62% |
| EPS Diluted | 96.15% | 96.47% | 50.17% | 23.94% | 6.89% |
| Normalized Diluted EPS | 95.99% | 96.35% | 48.20% | 20.88% | 10.62% |
| Average Basic Shares Outstanding | 662.62% | 5,907.92% | 4,661.29% | 3,328.78% | 1,404.33% |
| Average Diluted Shares Outstanding | 662.62% | 5,907.92% | 4,661.29% | 3,328.78% | 1,404.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |